Abstract
Since 2011, our team has developed and evaluated two integrase-based real-time PCR assays using a minor groove binder (mgb) probe specific for either SIVmnd-1 or SIVmnd-2. SIVmnd-1 RNA quantification was performed using a virus-specific plasmid (Invitrogen, Paisley, Scotland, United Kingdom) as an external qPCR standard. To date, a total of 66 independent samples have tested positive with the SIVmnd-1 assay. These included 62 SIVmnd-1 monoinfections versus 4 SIVmnd-1 and -2 coinfections (Figure 1). SIVmnd-1 RNA levels were globally high (median, 4.70 log10 copies/ml) but negatively affected by the presence of SIVmnd-2 (P < 0.001, analysis of variance [ANOVA]). Of note, among the five individuals showing VL results of 4.0 log10/ml were all SIVmnd-1 monoinfected. For SIVmnd-1 and -2 infections, given that sequential samplings were available, we were able to distinguish coinfections from superinfections as follows. Among the three experimental infections, one was a coinfection (dated October 2002) (MND 5A2), one was a superinfection with SIVmnd-1 (dated May 2001) in an individual already infected with SIVmnd-2 (dated December 1999) (MND 2C3), and one was a superinfection with SIVmnd-2 (dated July 2003) in an individual already infected with SIVmnd-1 (since November 2001) (MND 5A5). The natural infection was a superinfection with SIVmnd-1 (dated August 2002) in an individual infected with SIVmnd-2 since April 2001 (MND 12D4). The control for SIVmnd-1 viremia was either partial (MNDs 5A2, 5A5, and 12D4) or total (MND 2C3).